CEBP http://www.cancermicroenvironment.tau.ac.il/welcome2009.html Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Price, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Price, P. A.
Related Collections
Right arrow Epidemiology and Prevention
Right arrow Epidemiology and Prevention: Genetics and Biomarkers
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 194-202, February 2006
© 2006 American Association for Cancer Research


Review

Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?

Julia S. Johansen1, Benny Vittrup Jensen2, Anne Roslind2, Dorte Nielsen2 and Paul A. Price3

Departments of 1 Rheumatology and 2 Oncology, Herlev University Hospital, Herlev, Denmark; and 3 Department of Biology, University of California San Diego, La Jolla, California

Requests for reprints: Julia S. Johansen, Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Phone: 45-4488-4243; Fax: 45-4488-4214. E-mail: julia.johansen{at}post3.tele.dk.

YKL-40, a member of the "mammalian chitinase–like proteins," is expressed and secreted by several types of solid tumors. The exact function of YKL-40 in cancer diseases is unknown and is an important objective of future studies. YKL-40 exhibits growth factor activity for cells involved in tissue remodeling processes. YKL-40 may have a role in cancer cell proliferation, survival, and invasiveness, in the inflammatory process around the tumor, angiogenesis, and remodeling of the extracellular matrix. YKL-40 is neither organ- nor tumor-specific. However, the present retrospective clinical studies of patients with eight different types of primary or advanced solid tumors suggest that serum concentration of YKL-40 may be a new biomarker in cancer patients used as a "prognosticator." Elevated serum YKL-40 is found in a subgroup of patients with different types of solid tumors, including several types of adenocarcinomas, small cell lung carcinoma, glioblastoma, and melanoma. The highest serum YKL-40 is detected in patients with advanced cancer and with the poorest prognosis. In many cases, serum YKL-40 provides independent information of survival. Serum YKL-40 cannot be used as a single screening test for cancer. The use of serum YKL-40 has not received Food and Drug Administration approval for use as a biomarker for cancer or any other disease. Large multicenter retrospective and prospective studies of patients with different types of cancer are required to determine: (a) if serum YKL-40 is a useful prognostic cancer biomarker, (b) if serum YKL-40 can be of value in monitoring patients with cancer in order to provide information about metastases before these are detected by routine methods, and (c) if serum YKL-40 can be useful for screening of cancer together with a panel of other cancer biomarkers and imaging techniques. (Cancer Epidemiol Biomarkers Prev 2006;15(2):194–202)




This article has been cited by other articles:


Home page
Eur Heart JHome page
J. Kastrup, J. S. Johansen, P. Winkel, J. F. Hansen, P. Hildebrandt, G. B. Jensen, C. M. Jespersen, E. Kjoller, H. J. Kolmos, I. Lind, et al.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease
Eur. Heart J., May 1, 2009; 30(9): 1066 - 1072.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Johansen, S. E. Bojesen, A. K. Mylin, R. Frikke-Schmidt, P. A. Price, and B. G. Nordestgaard
Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population
J. Clin. Oncol., February 1, 2009; 27(4): 572 - 578.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. Mitsuhashi, H. Matsui, H. Usui, Y. Nagai, S. Tate, Y. Unno, K. Hirashiki, K. Seki, and M. Shozu
Serum YKL-40 as a marker for cervical adenocarcinoma
Ann. Onc., January 1, 2009; 20(1): 71 - 77.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. J. Biggar, J. S. Johansen, K. E. Smedby, K. Rostgaard, E. T. Chang, H.-O. Adami, B. Glimelius, D. Molin, S. Hamilton-Dutoit, M. Melbye, et al.
Serum YKL-40 and Interleukin 6 Levels in Hodgkin Lymphoma
Clin. Cancer Res., November 1, 2008; 14(21): 6974 - 6978.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. R. Nielsen, C. Erikstrup, J. S. Johansen, C. P. Fischer, P. Plomgaard, R. Krogh-Madsen, S. Taudorf, B. Lindegaard, and B. K. Pedersen
Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
Diabetes, November 1, 2008; 57(11): 3078 - 3082.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. S. Johansen, T. Lottenburger, H. J. Nielsen, J. E. B. Jensen, M. N. Svendsen, G. Kollerup, and I. J. Christensen
Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2603 - 2608.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Letuve, A. Kozhich, N. Arouche, M. Grandsaigne, J. Reed, M.-C. Dombret, P. A. Kiener, M. Aubier, A. J. Coyle, and M. Pretolani
YKL-40 Is Elevated in Patients with Chronic Obstructive Pulmonary Disease and Activates Alveolar Macrophages
J. Immunol., October 1, 2008; 181(7): 5167 - 5173.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. L. Kolson
YKL-40: A Candidate Biomarker for Simian Immunodeficiency Virus and Human Immunodeficiency Virus Encephalitis?
Am. J. Pathol., July 1, 2008; 173(1): 25 - 29.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Johansen, K. Brasso, P. Iversen, B. Teisner, P. Garnero, P. A. Price, and I. J. Christensen
Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival
Clin. Cancer Res., June 1, 2007; 13(11): 3244 - 3249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.